COLUMBUS, Ohio--(BUSINESS WIRE)--Wildix, a global leader in Unified Communications as a Service (UCaaS), today announced the launch of Sales Elevate Lab, the first-ever training program specifically ...
– Significant unmet need for safe and effective oral therapies in UC for patients with inadequate response, loss of response or intolerance to conventional or advanced therapies SAN DIEGO--(BUSINESS ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluating etrasimod, a ...
SAN DIEGO, June 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in ELEVATE UC 52, the first of two pivotal trials within the ...
- Significant unmet need for new effective therapies exists in ulcerative colitis - ELEVATE UC clinical trial sites continue to initiate SAN DIEGO, June 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, ...
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderately to severely active ulcerative colitis (UC) - Significant unmet need for new effective oral therapies in UC SAN DIEGO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results